EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 437 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR New Treatment Combinations Slow Progression of Prostate Cancer and Stomach and... February 5, 2024 FDA Proposes Changes to Mammography Standards to Inform Women About Breast... March 28, 2019 Adagrasib Shows Clinical Efficacy in Patients with Previously Treated KRASG12C-Mutated Advanced... June 9, 2022 Breaking down the new standards for cancer care proposed by NHS... March 11, 2022 Load more HOT NEWS Could Bacteria Help Find Cancer? Reunión anual de la ASCO de 2022: Gasto en servicios sociales... For Advanced Prostate Cancer, Radiopharmaceutical Improves Survival Evidence for the Utility of ctDNA Monitoring for Recurrence After CRC...
